QUEST DIAGNOSTICS INC (DGX) Insider Transactions
Over the last 12 months, 18 QUEST DIAGNOSTICS INC (DGX) insiders filed 167 SEC Form 4 transactions — $0 in open-market purchases ( 0 distinct buyers) and $38.6M in open-market sales. 4% of all transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.
- $0Open-market buys (1y)
- $38.6MOpen-market sells (1y)
- 18Distinct insiders
- 167Transactions filed
- 4%Under Rule 10b5-1 plan
- 2026-06-04Latest filing
Recent Form 4 Filings Most recent 50 of 167 (1-year window)
Each row is a single Form 4 filing event for DGX, sourced directly from SEC EDGAR. The Type column classifies the SEC transaction code into Buy / Sell / Grant / Exercise / Other; the 10b5-1 badge marks trades executed under a pre-scheduled SEC Rule 10b5-1 plan.
| Date | Insider | Title | Type | SEC Code | Value | Shares | Price |
|---|---|---|---|---|---|---|---|
| 2026-06-04 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Exercise 10b5-1 | M | $424.0K | 3,320 | $127.72 |
| 2026-06-04 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Exercise 10b5-1 | M | $588.0K | 4,827 | $121.81 |
| 2026-06-04 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Exercise 10b5-1 | M | $424.0K | 3,320 | $127.72 |
| 2026-06-04 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Exercise 10b5-1 | M | $588.0K | 4,827 | $121.81 |
| 2026-06-04 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Sell 10b5-1 | S | $1.6M | 8,147 | $200.00 |
| 2026-06-01 | Davis J. E. | CEO and President | Sell 10b5-1 | S | $1.9M | 10,000 | $194.14 |
| 2026-05-20 | Gregg Vicky B | — | Grant | A | $0 | 1,142 | $0.00 |
| 2026-05-20 | Diaz Luis | — | Grant | A | $0 | 1,142 | $0.00 |
| 2026-05-20 | MAIN TIMOTHY L | — | Grant | A | $0 | 1,142 | $0.00 |
| 2026-05-20 | WENTWORTH TIMOTHY C | — | Grant | A | $0 | 1,142 | $0.00 |
| 2026-05-20 | Doi Tracey | — | Grant | A | $0 | 1,142 | $0.00 |
| 2026-05-20 | RING TIMOTHY M | — | Grant | A | $0 | 1,142 | $0.00 |
| 2026-05-20 | Lassiter Wright III | — | Grant | A | $0 | 1,142 | $0.00 |
| 2026-05-20 | MORRISON DENISE M | — | Grant | A | $0 | 1,142 | $0.00 |
| 2026-05-20 | CARTER ROBERT B | — | Grant | A | $0 | 1,142 | $0.00 |
| 2026-05-20 | PFEIFFER GARY M | — | Grant | A | $0 | 1,142 | $0.00 |
| 2026-04-20 | SAMAD SAM | Executive Vice President & CFO | Grant | A | $21.0K | 108 | $194.70 |
| 2026-04-20 | Gregg Vicky B | — | Grant | A | $13.2K | 68 | $194.70 |
| 2026-04-20 | Plewman Patrick | SVP for Diagnostic Services | Other | L | $9.5K | 49 | $194.70 |
| 2026-04-20 | CARTER ROBERT B | — | Other | L | $1.4K | 7 | $194.70 |
| 2026-04-20 | Lassiter Wright III | — | Other | L | $1.2K | 6 | $194.70 |
| 2026-04-20 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Other | L | $7.6K | 39 | $194.70 |
| 2026-04-20 | DELANEY MARK E | SVP & Chief Commercial Officer | Other | L | $7.2K | 37 | $194.70 |
| 2026-04-01 | WENTWORTH TIMOTHY C | — | Grant | A | $0 | 198 | $0.00 |
| 2026-03-09 | WENTWORTH TIMOTHY C | — | Grant | — | $0 | 215 | $0.00 |
| 2026-03-05 | Doherty Catherine T. | EVP, Regional Businesses | Sell | — | $1.1M | 5,558 | $206.21 |
| 2026-03-05 | PREVOZNIK MICHAEL E | SVP & General Counsel | Sell | — | $799.7K | 3,878 | $206.21 |
| 2026-03-05 | Plewman Patrick | SVP for Diagnostic Services | Sell | — | $588.7K | 2,855 | $206.21 |
| 2026-03-04 | SAMAD SAM | Executive Vice President & CFO | Grant | — | $2.9M | 13,947 | $204.86 |
| 2026-03-04 | SAMAD SAM | Executive Vice President & CFO | Grant | — | $1.6M | 7,720 | $204.86 |
| 2026-03-04 | Doherty Catherine T. | EVP, Regional Businesses | Grant | — | $2.3M | 11,364 | $204.86 |
| 2026-03-04 | Doherty Catherine T. | EVP, Regional Businesses | Grant | — | $1.2M | 5,806 | $204.86 |
| 2026-03-04 | DELANEY MARK E | SVP & Chief Commercial Officer | Grant | — | $1.2M | 5,682 | $204.86 |
| 2026-03-04 | DELANEY MARK E | SVP & Chief Commercial Officer | Grant | — | $476.5K | 2,326 | $204.86 |
| 2026-03-04 | PREVOZNIK MICHAEL E | SVP & General Counsel | Grant | — | $1.5M | 7,232 | $204.86 |
| 2026-03-04 | PREVOZNIK MICHAEL E | SVP & General Counsel | Grant | — | $687.1K | 3,354 | $204.86 |
| 2026-03-04 | Davis J. E. | CEO and President | Grant | — | $10.6M | 51,652 | $204.86 |
| 2026-03-04 | Davis J. E. | CEO and President | Grant | — | $5.4M | 26,414 | $204.86 |
| 2026-03-04 | Plewman Patrick | SVP for Diagnostic Services | Grant | — | $1.2M | 5,682 | $204.86 |
| 2026-03-04 | Plewman Patrick | SVP for Diagnostic Services | Grant | — | $579.1K | 2,827 | $204.86 |
| 2026-03-04 | Deppe Michael J | SVP, Corp. Controller & CAO | Grant | — | $301.8K | 1,473 | $204.86 |
| 2026-03-04 | Deppe Michael J | SVP, Corp. Controller & CAO | Grant | — | $153.6K | 750 | $204.86 |
| 2026-03-04 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Grant | — | $1.3M | 6,200 | $204.86 |
| 2026-03-04 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Sell | — | $538.4K | 2,628 | $204.86 |
| 2026-03-03 | Doherty Catherine T. | EVP, Regional Businesses | Sell | — | $131.3K | 632 | $207.73 |
| 2026-03-03 | PREVOZNIK MICHAEL E | SVP & General Counsel | Sell | — | $109.3K | 526 | $207.73 |
| 2026-03-03 | Plewman Patrick | SVP for Diagnostic Services | Sell | — | $85.2K | 410 | $207.73 |
| 2026-03-02 | Doherty Catherine T. | EVP, Regional Businesses | Grant | — | $132.7K | 648 | $204.86 |
| 2026-03-02 | SAMAD SAM | Executive Vice President & CFO | Grant | — | $178.0K | 869 | $204.86 |
| 2026-03-02 | PREVOZNIK MICHAEL E | SVP & General Counsel | Grant | — | $59.0K | 288 | $204.86 |
Showing the most recent 50 of 167 transactions. For the full 1-year history with sorting, filtering, and cross-ticker industry context, open the full insider transactions drilldown.
Methodology & FAQ
How We Track DGX Insider Transactions
Form 4 disclosures are sourced directly from SEC EDGAR and re-ingested on every pipeline cycle. A complete description of transaction-code handling, the open-market vs grant distinction, and the Rule 10b5-1 plan-reference heuristic is documented in the Methodology.
What is an SEC Form 4 filing for QUEST DIAGNOSTICS INC?
Form 4 is a transaction-level disclosure that corporate insiders — officers, directors, and beneficial owners of more than 10% of a registered class of equity securities — must file with the SEC within two business days of any change in their beneficial ownership of QUEST DIAGNOSTICS INC (DGX) shares.
What is a Rule 10b5-1 trading plan?
Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Form 4 rows marked "10b5-1" on this page indicate the underlying trade was executed under such a plan; rows without the badge are discretionary or did not reference a plan in the Form 4 footnotes.
How is "insider buying" different from a stock grant or option exercise?
An insider buy (SEC transaction code P) is an open-market purchase of QUEST DIAGNOSTICS INC (DGX) stock executed at the prevailing market price using the insider's personal capital. Stock grants (code A) and option exercises (code M) are compensation events, not directional trades; they are tracked separately and excluded from the "conviction" signal because they are not discretionary purchases.
How recent is the data?
Form 4 transactions are typically reported within two business days of execution. Pactolio re-ingests the EDGAR feed on a nightly cycle and reflects new filings on the next ingest run, typically within 24 hours of EDGAR acceptance. The table on this page covers the most recent 1-year window.